Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach-Reference-Cited by-同舟云学术

Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach

Published:2017-11-20 Issue:1 Volume:25 Page:4-9
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Naylor P. H.¹,Mutchnick M. G.¹^ORCID

Affiliation:

1. Department of Internal Medicine/Gastroenterology; Wayne State University School of Medicine; Harper University Hospital; Detroit MI USA

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12807/fullpdf

Reference40 articles.

1. Current and future directions for treating hepatitis B virus infection;Tawada;World J Hepatol,2015

2. Management of chronic hepatitis B infection;Sundaram;BMJ,2015

3. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments;Tang;World J Gastroenterol,2014

4. Thymus-derived peptides in the treatment of viral chronic hepatitis;Naylor;Dig Dis,1996

5. Thymosin alpha-1 treatment in chronic hepatitis B;Wu;Expert Opin Biol Ther,2015

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenotypic drug discovery: a case for thymosin alpha-1;Frontiers in Medicine;2024-06-06

2. A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report;International Immunopharmacology;2023-04

3. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection;The Journal of Infectious Diseases;2022-09-03

4. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection;J INFECT DIS;2022

5. A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients;Indian Journal of Critical Care Medicine;2022-07-30